SLEEP APNEA DIAGNOSTIC SYSTEM MARKET ANALYSIS

The global sleep apnea diagnostic system market is estimated to be valued at US$ 10.7 billion in 2023 and is expected to exhibit a CAGR of 8.1% during the forecast period (2023-2030).

Analysts’ Views on Global Sleep Apnea Diagnostic System Market:

The prevalence of obesity and hypertension is rising, along with the occurrences of sleep apnea, the elderly population is growing, and the patient population in emerging nations is becoming more conscious of the condition. One of the main factors boosting the demand for sleep apnea devices is aging. The risk of acquiring this condition is highest among the elderly. The percentage of the world's population that is 65 years of age or older is expected to increase from 10% in 2022 to 16% in 2050, according to the World Population Prospects 2022. Globally, the number of people aged 65 and older is expected to surpass that of people under the age of 5 by 2050 and be almost equal to that of those under the age of 12.

Figure 1. Global Sleep Apnea Diagnostic System Market Share (%), by Product Type, 2023

To learn more about this report, request a free sample copy

Global Sleep Apnea Diagnostic System Market – Driver

Increasing product launches by the key market players

It is projected that the market would expand as a result of key market players are introducing new products to meet the increased demand for innovative products. As an illustration, to cover the gap created by the Philips CPAP recall, ResMed, medical device company, announced new sleep apnea equipment in August 2021. In a similar vein, GoPAPfree, a homecare provider of oral appliance therapy for obstructive sleep apnea, introduced O2Vent Optima in February 2021. This product is a highly effective and portable substitute for CPAP therapy.

Figure 2. Global Sleep Apnea Diagnostic System Market Value (US$ Billion), by Region, 2023

To learn more about this report, request a free sample copy

Global Sleep Apnea Diagnostic System Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global sleep apnea diagnostic system market over the forecast period. North America holds 41.5% of the market share. Approximately 15 to 30% of males and 10 to 15% of females in North America are predicted to have the condition, according to a study that was published in UpToDate, Inc., in January 2022. Furthermore, a 10% rise in weight was associated with a six-fold increase in the risk of Obstructive sleep apnea (OSA), according to the same study.

Global Sleep Apnea Diagnostic System Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a positive impact on the global sleep apnea diagnostic system market. For instance, patients with obstructive sleep apnea (OSA) had a 2.93 times greater risk of hospitalization when afflicted by COVID-19 than non-OSA persons, according to research published in the British Medical Journal (BMJ) Open Respiratory Research in January 2021.

Global Sleep Apnea Diagnostic System Market Segmentation:

The global sleep apnea diagnostic system market report is segmented into product type, end user, and region

Based on Product Type, the market is segmented into Polysomnography (PSG) Devices, (Ambulatory PSG Monitoring Devices, Clinical PSG Monitoring Devices), Sleep Apnea Screening Devices,(Nasal Flow Sensors, Peripheral Capillary Oxygen Saturation (SPO2)), and Actigraphy Monitoring Devices. Out of which, the Polysomnography (PSG) Devices segment is expected to hold a dominant position in the global sleep apnea diagnostic system market during the forecast period and this is attributed to the increase in technological advancement.

Based on End User, the market is segmented into Homecare Settings, Hospitals, Sleep Centers, and Clinics. Out of which, the Sleep Centers and Clinics segment is expected to dominate the market over the forecast period and this is attributed to the increase in the prevalence of obstructive sleep apnea which is leading towards the increase in a number of patient admissions in sleep centers and clinics.

Among all segmentation, the product type segment has the highest potential due to the increasing technological advancement in sleep apnea diagnostic systems over the forecast period. For instance, in September 2022, Onera Technologies B.V., a leader in transforming sleep medicine and remote monitoring, announced the official launch of its ground-breaking solution to diagnose sleep disorders in Europe. The service is based on the company’s Conformite Europeenne (CE)-marked and FDA-cleared Onera Sleep Test System and the Onera Digital Health Platform. It allows sleep professionals to conduct sleep studies in the comfort of the patient’s home while maintaining clinical-grade quality as with in-lab diagnostics.

Global Sleep Apnea Diagnostic System Market Cross Sectional Analysis:

Obstructive sleep apnea (OSA) is strongly associated with cardiovascular disease (CVD),  is leading towards an increasing number of patient admissions in the sleep centers and clinics which is expected to drive the growth of the global sleep apnea diagnostic system market over the forecast period. For instance, according to the article published in National Center for Biotechnology Information, in June 2022, it is stated that a few studies in Asia have reported an OSA prevalence ranging from 4.1% to 7.5% in men and from 2.1% to 4.5% in women, with an overall prevalence of 8.5% in the general adult population aged >18 years.